Want to see FR:DIM full AI Analyst Report?
DIM Stock Chart & Stats
€188.70
€3.85(1.94%)
At close: 4:00 PM EST
€188.70
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€150.00 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€17.84B
Enterprise Value€19.29B
Total Cash (Recent Filing)€521.20M
Total Debt (Recent Filing)€2.61B
Price to Earnings (P/E)68.8
Beta1.49
Next Earnings
Jul 23, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)2.75
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€225.67Price Target Upside19.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.08
Revenue Forecast (FY)€3.17B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueA high-share recurring consumables model creates predictable, repeat revenue tied to customers' production runs. Installed capital placements drive long-term pull-through for disposables, smoothing demand cycles and supporting durable revenue and margin visibility over multiple quarters.
Revenue Re-acceleration & Operating ProfitabilityA sharp TTM revenue rebound alongside solid EBIT/EBITDA margins signals renewed end-market demand and operational scalability. Sustained top-line momentum combined with healthy operating margins improves prospects for medium-term cash generation and reinvestment capacity.
Improving Leverage / Balance Sheet RepairMaterial reduction in leverage improves financial flexibility and lowers refinancing risk. A more manageable debt load enhances capacity to fund R&D, capex or strategic deals without jeopardizing operational stability over the next several quarters.
Bears Say
Margin Compression Vs PeakMeaningful, multi-year margin erosion versus 2021–2022 peaks reduces the company's earnings power per euro of revenue. If structural (pricing, mix, or cost base shifts), this compresses long-term profitability, ROE, and available cash for reinvestment or shareholder returns.
Weak Free Cash Flow ConversionLow conversion of earnings into free cash flow suggests working-capital drag or elevated reinvestment need. Persistently weak FCF conversion limits self-funding of growth initiatives, reduces ability to accelerate debt reduction, and constrains distributions to shareholders.
Modest Return On Equity With Material DebtSubdued ROE alongside material outstanding debt implies limited effectiveness in converting equity capital into returns. This combination may restrain capital allocation choices and shareholder value creation absent sustained margin or growth improvement.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €150.00 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €17.84B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Jul 23, 2026 which is in 9 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Apr 23, 2026. The company reported €1.17 earnings per share for the quarter, missing the consensus estimate of €1.211 by -€0.041.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.26.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.17 in its last earnings report, missing expectations of €1.211. Following the earnings report the stock price went down -14.185%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
DIM Stock 12 Month Forecast
Average Price Target
€225.67
▲(19.59% Upside)
Technical Analysis
Options Prices
Currently, No data available
---









